Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson Disease: early-phase trial registry
135 of 298 indexed Parkinson Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #31 of 28,707 conditions by registered trial count.
298 US clinical trials · 135 currently recruiting · #31 of 28,707 conditions by registered trial count
Parkinson Disease: 298 US clinical trials tracked, 135 recruiting.
Parkinson Disease is the subject of 298 registered US clinical trials on ClinicalTrials.gov, 135 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 10 of these trials.
Enrollment posture brief
Registry condition parkinson-disease
OPEN 135 | RECR 45% | LATE 21 | EARLY 66 | RANK #31 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Parkinson Disease lists 135 open slots (45% of 298 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson Disease is recruiting above its size-band peers.
135 of 298 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Parkinson Disease trials is spread across many organizations.
University of Minnesota accounts for 10 of 298 trials (3.4%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinson Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 298 trials that report a genuine target (sentinel values excluded). 207 of those (69.5%) plan for fewer than 100 participants.
-
Parkinson Disease research is mostly interventional.
226 interventional and 72 observational studies make up this index (75.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
298 total, page 4 of 6
Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
Abbott Medical Devices
NCT05269862
Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)
Teachers College, Columbia University
NCT04922190
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Aptinyx
NCT04148391
Neuro-immune Interactome in Parkinson's Disease
Yale University
NCT07026929
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
InSightec
NCT03319485
Non-invasive Brain Mapping of Movement Facilitation in Parkinson's Disease
University of California, Los Angeles
NCT05179187
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Massachusetts General Hospital
NCT04753320
Parkinson's Disease Progression Study
Koneksa Health
NCT06219629
Sing For Your Saunter Part 2 R33
Washington University School of Medicine
NCT06115382
Home Based Tele-exercise for People With Chronic Neurological Impairments
Burke Medical Research Institute
NCT04564495
Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
Oregon Health and Science University
NCT04897256
FDOPA PET and Nutritional Support in Parkinson's Disease
Thomas Jefferson University
NCT04459052
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
InSightec
NCT04728295
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™
Michael J. Fox Foundation for Parkinson's Research
NCT04507139
Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Patients
Sanford Health
NCT03191916
RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease
University of Alabama at Birmingham
NCT03305588
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
Spaulding Rehabilitation Hospital
NCT03981055
Functional Neuroimaging in Parkinson's Disease
University of Delaware
NCT04904068
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Prevail Therapeutics
NCT04127578
Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study
Northwestern University
NCT03667404
The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy
University of California, San Francisco
NCT03582891
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
Emory University
NCT06295458
Repurposing Lithium for Parkinson's Disease: a RCT
State University of New York at Buffalo
NCT06339034
Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease
University of Nebraska
NCT04620551
Subcortical Oscillations in Human Sleep Dysregulation
University of Colorado, Denver
NCT03377569
Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease
James Liao
NCT05022147
Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT
University of Pennsylvania
NCT04062526
Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson's Disease
Doris Wang, MD, PhD
NCT04675398
HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)
Dartmouth-Hitchcock Medical Center
NCT06260228
Blood Flow Restriction and Exercise in Parkinson's Disease
University of California, San Francisco
NCT07221994
Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)
Boehringer Ingelheim
NCT00617019
Parkinson's Disease in African American and Caucasian Patients
University of Chicago
NCT03279445
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
Pfizer
NCT00036218
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Pharma Two B
NCT03329508
Speech Accessibility Project
University of Illinois at Urbana-Champaign
NCT05889260
Physiological Brain Atlas Development
Ohio State University
NCT01210534
Synuclein-One Study
CND Life Sciences
NCT04700722
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
GlaxoSmithKline
NCT00632736
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
GlaxoSmithKline
NCT01494532
Flexible-Dose Trial in Early Parkinson's Disease (PD)
AbbVie
NCT04223193
PET Study of Non-Motor Symptoms of Parkinson Disease
University of Michigan
NCT01565473
Opicapone Treatment Initiation Open-Label Study
Neurocrine Biosciences
NCT04787965
Light Therapy for PD - Dose Selection
Massachusetts General Hospital
NCT04291014
NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
University of Rochester
NCT00076492
STEM-Parkinson's Disease
Scion NeuroStim
NCT04797611
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
Enterin
NCT03781791
Social Self-Management of Parkinson's Disease
Tufts University
NCT03938974
FoxBioNet: ECV (Extracellular Vesicle) 004
Michael J. Fox Foundation for Parkinson's Research
NCT04603326
How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00040196
Wearable Assessments in the Clinic and Home in PD
University of Rochester
NCT03681015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 35 |
| Phase 3 | 8 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson Disease page
298 registered trials, 135 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 135 Parkinson Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Minnesota sponsors the most Parkinson Disease trials on record, review their full trial history before evaluating a specific study. See University of Minnesota's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson Disease condition card totals 298 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.